<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860197</url>
  </required_header>
  <id_info>
    <org_study_id>immunecoffee</org_study_id>
    <nct_id>NCT00860197</nct_id>
  </id_info>
  <brief_title>Immune Benefits of Coffee</brief_title>
  <official_title>Effect of Coffee Consumption on Immune and Inflammatory Status in Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nestl√©</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether coffee consumption:&#xD;
&#xD;
        -  increases immune responses&#xD;
&#xD;
        -  decreases inflammatory status&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiological studies suggest that coffee consumption is associated with protective effects&#xD;
      against several types of chronic diseases. Recent data have shown that certain coffee&#xD;
      components may possess anti-inflammatory and immune-enhancing properties. Low-grade&#xD;
      inflammation and poor capacity of immune response is highly prevalent in elderly subjects.&#xD;
&#xD;
      The purpose of this study is to evaluate whether coffee consumption improves immune and&#xD;
      inflammatory status in healthy elderly subjects. To sort out the role of antioxidants, we&#xD;
      will test 2 different soluble coffee, i.e. fully torrefied coffee and partially torrefied&#xD;
      coffee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NK-cell activity</measure>
    <time_frame>will be measured before and after 30 days +/- treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tuberculin test</measure>
    <time_frame>will be measured before and after 30 days +/- treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory status</measure>
    <time_frame>will be measured before and after 30 days +/- treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota profiling</measure>
    <time_frame>will be measured before and after 30 days +/- treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Immune Senescence</condition>
  <condition>Low-grade Inflammation</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No coffee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fully torrefied coffee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Partially torrefied coffee</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fully torrefied coffee</intervention_name>
    <description>Fully torrefied coffee</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Partially torrefied coffee</intervention_name>
    <description>Partially torrefied coffee</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, self-sufficient, free-living Chilean elderly&#xD;
&#xD;
          -  Having the ability to comprehend the procedures of the study&#xD;
&#xD;
          -  Having obtained his/her informed consent after verbal and written information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects drinking more than 2 cups of coffee per day&#xD;
&#xD;
          -  Subjects with rapidly deteriorating health status at enrolment in the study&#xD;
&#xD;
          -  Subjects with terminal or acute disease, or unstable health status&#xD;
&#xD;
          -  Subjects with chronic disease: chronic respiratory illness; chronic diseases of the&#xD;
             pulmonary or cardiovascular systems (including asthma); chronic metabolic disease&#xD;
             (diabetes); chronic renal disease, organ failure&#xD;
&#xD;
          -  Subjects with serious neurological disorder, including dementia (MMSE &lt; 20) or&#xD;
             Alzheimer's disease&#xD;
&#xD;
          -  Subjects who have experienced rapid weight loss, chronic diarrhea (loose stools, 3&#xD;
             times daily), or Crohn's (IBD)&#xD;
&#xD;
          -  Subjects with gastrointestinal problems&#xD;
&#xD;
          -  Subjects with a hospitalization planned during this study&#xD;
&#xD;
          -  Subjects who have received any antibiotic treatment during the last 3 months prior to&#xD;
             the beginning of this study&#xD;
&#xD;
          -  Subjects who had a colonoscopy performed during the last 3 months prior to the&#xD;
             beginning of this study&#xD;
&#xD;
          -  Subjects with immune deficiency diseases (e.g. HIV infection)&#xD;
&#xD;
          -  Subjects with a history of allergy - especially to egg protein, egg, shellfish or the&#xD;
             antibiotics polymyxin or neomycin&#xD;
&#xD;
          -  Subjects receiving medication that may influence the immune system (i.e.&#xD;
             corticosteroids, immuno-suppressors and immuno-modulators, antimicrobials)&#xD;
&#xD;
          -  Subjects who have received any vaccination during the last 15 days prior to baseline&#xD;
&#xD;
          -  Subjects who are expected to be non-compliant&#xD;
&#xD;
          -  Subjects currently participating or having participated in another clinical trial&#xD;
             during the last 3 months prior to the beginning of this study&#xD;
&#xD;
          -  Subjects participating in another research study involving any type of medication&#xD;
             related to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Bunout, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INTA University of Chile, Santiago, Metropolitana, Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INTA University of Chile</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <zip>7830489</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <link>
    <url>http://www.inta.cl</url>
    <description>Web site of INTA University of Chile</description>
  </link>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chile</investigator_affiliation>
    <investigator_full_name>Daniel Bunout</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Coffee</keyword>
  <keyword>Elderly</keyword>
  <keyword>Immune response</keyword>
  <keyword>Inflammatory status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

